BioVie (NASDAQ:BIVI – Get Free Report) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.29) EPS for the quarter. On average, analysts expect BioVie to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
BioVie Trading Down 3.7 %
BIVI stock opened at $1.03 on Tuesday. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 0.39. BioVie has a 12 month low of $0.89 and a 12 month high of $11.39. The firm has a 50-day moving average of $1.40 and a two-hundred day moving average of $2.90.
Institutional Trading of BioVie
Wall Street Analysts Forecast Growth
A number of analysts have commented on BIVI shares. Oppenheimer cut their price objective on shares of BioVie from $12.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, November 30th. Cantor Fitzgerald downgraded shares of BioVie from an “overweight” rating to a “neutral” rating in a report on Thursday, November 30th.
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
- Five stocks we like better than BioVie
- How to Invest in Mining Stocks
- Skechers stocks trips on inventory bloat, but there’s an upside
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 transportation stocks gearing up for a new rally
- How to Invest in the Best Canadian Stocks
- This mid-cap tech stock just jumped 30%…and is still cheap
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.